Investigational drug · Phase 3
AXS-07
Also called: meloxicam-rizatriptan
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Migraine.
Phase 3Last checked: Nov 19, 2026Latest source record: Dec 2, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "AXS-07"
First trial start
2022
Aug 31, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AXS-07", any sponsor or status.
Conditions studied
As listed on its trial records.
- Migraine
Approved drugs for the same conditions: Migraine · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "AXS-07" as an intervention, largest first.
- Maximizing Outcomes in Treating Acute MigrainePivotal-lookingCompleted
Axsome Therapeutics, Inc.Industry
NCT03896009 · 1,594 participants · Start Mar 4, 2019 · Primary completion Dec 10, 2019
Drug: AXS-07 (MoSEIC meloxicam and rizatriptan); Meloxicam and 2 more · For: Migraine
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 85 sites in all
- Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)Pivotal-lookingCompleted
Axsome Therapeutics, Inc.Industry
NCT04068051 · 706 participants · Start Jul 6, 2019 · Primary completion Sep 22, 2020
Drug: AXS-07 · For: Migraine
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 51 sites in all
- Initiating Early Control of Migraine Pain and Associated SymptomsPivotal-lookingCompleted
Axsome Therapeutics, Inc.Industry
NCT04163185 · 302 participants · Start Oct 8, 2019 · Primary completion Mar 16, 2020
Drug: AXS-07 (MoSEIC meloxicam and rizatriptan); Placebo · For: Migraine
Sites: Birmingham, Alabama; Mobile, Alabama; Colton, California · 41 sites in all
- Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)Pivotal-lookingCompleted
Axsome Therapeutics, Inc.Industry
NCT05550207 · 100 participants · Start Aug 31, 2022 · Primary completion Nov 27, 2024
Drug: AXS-07 (meloxicam-rizatriptan) · For: Migraine
Sites: Colton, California; Fullerton, California; La Jolla, California · 31 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Migraine
- EVO756Phase 24 trials
Evommune, Inc. · Migraine, Chronic Inducible Urticaria, Atopic Dermatitis
- BHV-2100Phase 21 trial
Biohaven Therapeutics Ltd. · Migraine
- MEDI0618Phase 21 trial
AbbVie · Migraine
- MTX101Phase 21 trial
Manistee Therapeutics · Migraine
- PRT-064040Phase 21 trial
Sichuan Purity Pharmaceutical Technology Co., Ltd. · Migraine
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.